Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04717453 · ClinicalTrials.gov registry record
Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 1
- Enrollment target
NCT04717453 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 1 participants.
The verdict
NCT04717453 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of ureagenesis and executive and verbal function and characterize the association of rate of ureagenesis and patient-reported functional status.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2021-12-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04717453
The ClinicalTrials.gov registry entry for NCT04717453 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04717453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04717453 about?
NCT04717453 is a clinical study titled "Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency". The objectives of the study are to characterize urea production rates in patients with OTC, characterize the association of rate of ureagenesis and disease severity in OTC patients, characterize the association of rate of ureagenesis and executive and verbal function and characterize the association...
What is the current status of trial NCT04717453?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2020-10-06. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT04717453?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04717453?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.